Valsartan exposure in pregnancy with resultant anhydramnios and chronic kidney disease in a late preterm infant
作者： Sarah Petch , Emily O'Connor , Ailbhe McGrath , Sean Daly
关键词: Kidney disease 、 Valsartan 、 In utero 、 Late preterm infant 、 Internal medicine 、 Obstetrics 、 Oligohydramnios 、 Pregnancy 、 Gestation 、 Medicine 、 Nephrology
摘要: In utero exposure to angiotensin II receptor blockers (ARBs) has fetotoxic effects including renal failure, oligohydramnios and lung hypoplasia. We present the case of a 24-year-old woman who presented maternity services in 34th week her first pregnancy. She was taking valsartan for hypertension. Ultrasound showed structurally normal fetus with anhydramnios. The patient admitted discontinued. had spontaneous preterm delivery at 35 weeks' gestation baby girl. baby's urine output minimal life she transferred paediatric hospital specialist nephrology input. At 6 months age, requires ongoing follow-up remains on treatment hypertension anaemia. This demonstrates serious adverse resulting from ARB utero, highlights importance avoiding medications women childbearing age.
sci-hub.st 参考文章(25)
Amy Barreras, Cheryle Gurk-Turner, Angiotensin II receptor blockers Proceedings (Baylor University. Medical Center). ,vol. 16, pp. 123- 126 ,(2003) , 10.1080/08998280.2003.11927893
Marc Oppermann, Stephanie Padberg, Angela Kayser, Corinna Weber-Schoendorfer, Christof Schaefer, Angiotensin-II receptor 1 antagonist fetopathy--risk assessment, critical time period and vena cava thrombosis as a possible new feature. British Journal of Clinical Pharmacology. ,vol. 75, pp. 822- 830 ,(2013) , 10.1111/J.1365-2125.2012.04388.X
Emmanuel Spaggiari, Laurence Heidet, Gilles Grange, Fabien Guimiot, Sophie Dreux, Anne-Lise Delezoide, Françoise Muller, , Prognosis and outcome of pregnancies exposed to renin–angiotensin system blockers Prenatal Diagnosis. ,vol. 32, pp. 1071- 1076 ,(2012) , 10.1002/PD.3960
Scott R. Yoder, Loralei L. Thornburg, John D. Bisognano, Hypertension in pregnancy and women of childbearing age. The American Journal of Medicine. ,vol. 122, pp. 890- 895 ,(2009) , 10.1016/J.AMJMED.2009.03.036
Doreen Matsui, Adherence with drug therapy in pregnancy. Obstetrics and Gynecology International. ,vol. 2012, pp. 796590- 796590 ,(2012) , 10.1155/2012/796590
Brian T. Bateman, Pooja Bansil, Sonia Hernandez-Diaz, Jill M. Mhyre, William M. Callaghan, Elena V. Kuklina, Prevalence, trends, and outcomes of chronic hypertension: a nationwide sample of delivery admissions. American Journal of Obstetrics and Gynecology. ,vol. 206, pp. 134- ,(2012) , 10.1016/J.AJOG.2011.10.878
Albert Quan, Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Human Development. ,vol. 82, pp. 23- 28 ,(2006) , 10.1016/J.EARLHUMDEV.2005.11.001
S. Alwan, J.E. Polifka, J.M. Friedman, Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Research Part A-clinical and Molecular Teratology. ,vol. 73, pp. 123- 130 ,(2005) , 10.1002/BDRA.20102
U. Martin, M. A. Foreman, J. C. Travis, D. Casson, J. J. Coleman, Use of ACE inhibitors and ARBs in hypertensive women of childbearing age. Journal of Clinical Pharmacy and Therapeutics. ,vol. 33, pp. 507- 511 ,(2008) , 10.1111/J.1365-2710.2008.00938.X
Claudio Celentano, Federico Prefumo, Elena di Vera, Annamaria Iannicco, Davide Pio Gallo, Marco Liberati, Reversible acute fetal renal failure due to maternal exposure to angiotensin receptor blocker Pediatric Nephrology. ,vol. 23, pp. 333- 334 ,(2008) , 10.1007/S00467-007-0618-8